ArticleNature communications2018
Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 100 citations in OpenAlex.
- MicroRNA-124-targeted recombinant Zika virus: a dual-functional and safe candidate for vaccination and oncolytic virotherapy.Journal of virology · 2026Article
- Reverse Genetics of Orthoflaviviruses: Strategies for Constructing Functional or Infectious cDNA.Journal of medical virology · 2026Review
- Intracranial injection of genetically modified, mosquito non-transmissible Zika virus: Safety in primates and ramifications for brain tumor therapy.Cell reports. Medicine · 2025Article
- Thioester-Containing Protein TEP27 inInternational journal of molecular sciences · 2025Article
- Bioprofiling and vaccine development for Zika virus.Science China. Life sciences · 2025Review
- A nitrogen-containing diphyllin derivative C156-P1 exhibited broad-spectrum antiviral activity againstAntimicrobial agents and chemotherapy · 2025Article
- Manipulating Zika virus RNA tertiary structure for developing tissue-specific attenuated vaccines.EMBO molecular medicine · 2025Article
- One Health Approach in the Era of Emerging Viruses: The Challenge of Usutu Virus.International journal of molecular sciences · 2025Review
- Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development.The Lancet. Infectious diseases · 2025Review
- Role of non-human primate models in accelerating research and developing countermeasures against Zika virus infection.The Lancet. Microbe · 2025Review
- Review
- Comparison of Three Chimeric Zika Vaccine Prototypes Developed on the Genetic Background of the Clinically Proven Live-Attenuated Japanese Encephalitis Vaccine SAInternational journal of molecular sciences · 2024Article
- Article
- A review on Zika vaccine development.Pathogens and disease · 2024Review
- Epitope screening and vaccine molecule design of PRRSV GP3 and GP5 protein based on immunoinformatics.Journal of cellular and molecular medicine · 2024Article
- EDIII-Fc induces protective immune responses against the Zika virus in mice and rhesus macaque.PLoS neglected tropical diseases · 2023Article
- Flaviviruses in AntiTumor Therapy.Viruses · 2023Review
- Rapid Generation of Recombinant Flaviviruses Using Circular Polymerase Extension Reaction.Vaccines · 2023Article
- Novel approaches for the rapid development of rationally designed arbovirus vaccines.One health (Amsterdam, Netherlands) · 2023Article
- An effective live-attenuated Zika vaccine candidate with a modified 5' untranslated region.NPJ vaccines · 2023Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 4 countries.
Funding
Abstract
The global spread of Zika virus (ZIKV) and its unexpected association with congenital defects necessitates the rapid development of a safe and effective vaccine. Here we report the development and characterization of a recombinant chimeric ZIKV vaccine candidate (termed ChinZIKV) that expresses the prM-E proteins of ZIKV using the licensed Japanese encephalitis live-attenuated vaccine SA14-14-2 as the genetic backbone. ChinZIKV retains its replication activity and genetic stability in vitro, while exhibiting an attenuation phenotype in multiple animal models. Remarkably, immunization of mice and rhesus macaques with a single dose of ChinZIKV elicits robust and long-lasting immune responses, and confers complete protection against ZIKV challenge. Significantly, female mice immunized with ChinZIKV are protected against placental and fetal damage upon ZIKV challenge during pregnancy. Overall, our study provides an alternative vaccine platform in response to the ZIKV emergency, and the safety, immunogenicity, and protection profiles of ChinZIKV warrant further clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.